Table 2.
Adverse events in patients taking cilostazol compared to controls taking antiplatelet therapy.
| Adverse event | Cilostazol (n, %) |
Control (n, %) |
Odds ratio (95% CI) |
|---|---|---|---|
| Major Bleeding | 79/4211, 1.9% |
102/4176, 2.4% |
0.73 (0.54–0.99) |
| Headache | 743/4804, 15.5% |
413/4778, 8.6% |
2.00 (1.76–2.28) |
| Dizziness | 349/3419, 10.2% |
292/3418, 8.5% |
1.22 (1.04–1.44) |
| Palpitations | 281/4566, 6.2% |
124/4581, 2.7% |
2.29 (1.87–2.80) |
| Diarrhea | 303/2434, 12.5% |
126/2403, 5.2% |
2.42 (1.99–2.96) |
| Constipation | 189/2334, 8.1% |
268/2330, 11.5% |
0.68 (0.56–0.82) |
| Nausea | 76/1548, 4.9% |
53/1547, 3.4% |
1.47 (1.02–2.11) |